IBBQ iShares Biotechnology ETF Loading...

Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
08:42
Jul 15
Park Se-ik CEO, ex-Chief Strategist Chesley Investment Advisory (…
Korean biotech sector set for rebound.
The Korean biotech/healthcare sector has been heavily sold off and is deeply underperforming KOSPI and KOSDAQ. The sell-off is driven by temporary trust issues (disclosure scandals at Alteogen and Samchundang Pharm) and fund outflows to semiconductor levered products, not by fundamental deterioration. Sector fundamentals are strong with 16% revenue growth and rising R&D output. Multiple H2 catalysts—including the 150 trillion won government growth fund targeting biotech, big pharma licensing deals due to patent expiries, and upcoming clinical data—support a rebound from deeply depressed levels.
IBBQ 1ST
MED

About IBBQ Analyst Coverage

Buzzberg tracks IBBQ (iShares Biotechnology ETF) across 1 sources. 1 bullish vs 0 bearish calls from 1 analysts. Sentiment: predominantly bullish (100%). 1 total trade idea tracked. Past 7 days: 1 bullish. Latest voices: Park Se-ik.